Alix Ventures focuses on investing in transformative companies in the life sciences sector, particularly in the TechBio space, to improve patient care.

Alix Ventures

Biotechnology Research

Alix Labs

Alix Ventures | 4,180 followers on LinkedIn. Supporting Life Science Platforms Building The Future Of Medicine ✨ | Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health

Born from our collective experience as founders, we set out to build the fund we wanted to raise from...

Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology &amp; biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality &amp; effectiveness of patient care.

Operating Partner @ Alix Ventures | Board Member @ Inovalon | Proprietor @ Pulido ~ Walker Cellars

Mark Pulido

Founder at Mythic Therapeutics

Brian Fiske

General Partner @ Alix Ventures | Creator @ BIOS

Chas Pulido

Olaide Gbade

Born from our collective experience as founders, we launched Alix Ventures to back early stage startups driving patient impact 🚀 #healthcare #lifesciences #innovation #startups #venturecapital #earlystage #founders #drivingpatientimpact https://lnkd.in/d4C96Mq

🎙️ Biophysics and Rejuvenation w/ Stephen Quake, D.Phil. - Professor @ Stanford University Thrilled to re- share our podcast episode featuring the renowned Stephen Quake, co-President of the Chan Zuckerberg Biohub and Professor at Stanford University. We delve into his fascinating journey from physics to bioengineering, exploring how his pioneering work is revolutionizing early cancer detection through liquid biopsies. Stephen shares his insights on the lessons learned from the Theranos scandal, emphasizing the importance of integrity and scientific rigor in the biotech industry. We also discuss his involvement with Veblen and the Eleftheria Foundation, two organizations at the forefront of driving innovative solutions for global health challenges. This episode is packed with valuable takeaways for entrepreneurs, scientists, and anyone passionate about the future of life sciences. Tune in:

Deep Dive: Drug Repurposing & Reengineering The innovative field of #DrugRepurposing and #Reengineering is transforming biopharma by breathing new life into existing drug compounds. This approach leverages our advanced understanding of network and systems biology, along with cutting-edge technologies like #AI and #ComputationalBiology , to uncover new uses for drugs that have already been through rigorous clinical testing. By bypassing early trial phases, these repurposed drugs can move directly to Phase II trials, significantly reducing development costs and time to market. This not only provides a quicker route to effective treatments but also addresses the urgent needs in underserved disease areas. Dive into our latest article to explore how medium and large biopharma companies are harnessing these strategies to deliver innovative solutions and improve patient outcomes globally. Tune in:

🧱 Builders w/ Maddison Masaeli - Co-Founder & CEO @ Deepcell 🚀 Excited to share our latest podcast episode featuring Maddison Masaeli, Co-founder & CEO of @Deepcell! In this insightful conversation, Maddison delves into Deepcell’s innovative approach to single-cell imaging and analysis, shedding light on their groundbreaking technology and its transformative impact on diagnostic testing and therapeutics. Discover how their ambitious project is building the world’s largest database of cellular morphologies and explore the future of precision medicine. Don’t miss this chance to gain valuable insights into the cutting-edge developments shaping the future of healthcare. 🎧 Tune in:

Deep Dive: Longevity Therapeutics 🌟 Exciting developments in the field of longevity therapeutics! Unity Biotech’s Phase II trial for osteoarthritis could be a game-changer in senolytic therapies. This innovative compound targets and eliminates senescent cells, potentially improving quality of life and healthspan. Additionally, the ongoing study of dasatinib and quercetin (D+Q) is showing promising results in removing senescent cells. The big question remains: will these interventions translate to tangible health benefits? Dive into our detailed article to explore the potential future impact of these groundbreaking research efforts on aging and longevity interventions. Read more: https://buff.ly/4cf9P5v #Longevity #AgingResearch #Healthspan #Senolytics #BiotechInnovation #ClinicalTrials

Frontier Science - Advanced Microfluidics✨ w/ Albert Folch - Professor @ University of Washington We are thrilled to re-share our episode on BIOS Frontier Science, featuring Albert Folch, Associate Professor of Bioengineering at the University of Washington. Join us as we delve into the revolutionary world of microfluidic devices and explore how Albert Folch's team is pushing the boundaries of bioengineering through innovative 3D printing and automation techniques. From improving cancer diagnostics to pioneering cellular micropatterns, this episode is packed with insights on the future of this dynamic field. Tune in to gain a deeper understanding of the challenges and opportunities in microfluidics and hear Albert's vision for the next decade. Don't miss this enlightening conversation—click the link to listen now! Tune in: https://buff.ly/3A6xdEz #Bioengineering #Microfluidics #Innovation #SciencePodcast #FutureTech

🧱 Builders w/ Eric Kelsic - Co-Founder & CEO @ Dyno Therapeutics Dive deep into the future of gene therapies as Eric discusses the innovative CapsidMap™ platform, which uses AI to optimize AAV capsids for better targeting, payload size, immune evasion, and manufacturability. Learn about the cutting-edge techniques Dyno employs, including DNA library synthesis, high-throughput measurement, and machine learning models, to revolutionize viral vector development and advance the field of gene therapy. Eric also shares the challenges and successes faced by Dyno, their $100M Series A funding, and the transformative potential of their technology. Whether you're a biotech enthusiast, a researcher, or just curious about the future of medicine, this episode is packed with insights and visionary perspectives. Don't miss out—tune in now to discover how Dyno Therapeutics is shaping the future of gene therapy! Tune in:

Deep Dive: Organoids Organoids, self-organizing 3D structures grown from stem cells, are revolutionizing early-stage drug development and beyond. Mimicking the architecture and behavior of human organs, they offer a realistic in vivo environment that enhances pre-clinical safety and efficacy studies. This breakthrough technology promises to reduce costs, improve translation from lab to clinic, and open new horizons in regenerative and precision medicine. Whether derived from pluripotent stem cells or adult stem cells, organoids are poised to transform healthcare by enabling more accurate models and personalized therapies. Dive into our latest article to explore how organoids are shaping the future of medicine and making groundbreaking strides in biotechnology and pharmaceuticals. 🌐💉 #HealthcareInnovation #DrugDevelopment #RegenerativeMedicine #PrecisionMedicine #Biotech #MedTech #Research Read the full article here:

Frontier Science - Supramolecular Biomaterials💥 w/ Eric Appel - Professor @ Stanford Join us as we explore Eric Appel's pioneering research on supramolecular hydrogels and their transformative potential in drug delivery and regenerative medicine. Eric discusses the development of advanced hydrogels for targeted cancer therapy and wound healing, and the innovative excipients his team is creating for protein therapeutics like insulin through his company, Surf Bio. Discover how these breakthroughs are not only enhancing therapeutic applications but also extending to wildfire prevention. Tune in for an in-depth look at the future of materials science and its real-world impact! Tune in:

Builders #8 w/ Fabian Gerlinghaus - Co-Founder & CEO @ Cellares In case you missed it! We're excited to re-share our podcast episode featuring Fabian Gerlinghaus, Co-founder & CEO of Cellares. Dive deep into the world of cell therapy manufacturing as Fabian recounts the journey of Cellares from its inception to pioneering end-to-end automation in cell therapy production. Rediscover the key challenges in the industry today, how Cellares' innovative approach is reducing costs and increasing patient access, and the impact of their technology on early R&D timelines. Plus, gain insights into how Cellares is scaling to meet future patient demand and exploring the potential of AI-driven biomanufacturing. This episode remains a must-listen for biotech enthusiasts, healthcare innovators, and industry professionals eager to learn about cutting-edge advancements in cell therapy manufacturing. See how Cellares is transforming the field and shaping the future of patient care. Tune in now:

Viewport Meta

SSL by Default

Google Font API

HSTS

Content Delivery Network

DNSSEC

LetsEncrypt

Google Apps for Business

YouTube

COVID-19

Founder & General Partner

Venture Capital University Ambassador

Aaron Edwards

Chief of Staff

Christopher Ghadban

Business Management

Jim Ameduri

Operating Partner

Daniel Delubac

Jacob Becraft

Founder and General Partner

Using the power of circular RNA to control any gene, in any species, in any cell type

Venture Capital Investors with Investments in Greater San Diego Area

Investors Active in Southern US (Top 10K)

Venture Capital Investors with Investments in Durham, North Carolina

Venture Capital Investors with Investments in San Carlos, California

Alix Ventures: Driving Patient Impact - Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health

Born from our collective experience as founders, we set out to build the fund we wanted to raise from...

Thesis: Life Sciences is experiencing rapid innovation with the rise of TechBio, a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences.

Team: Our entire team is composed of serial VC backed Life Sciences founders with experience in raising capital, scaling teams, running labs, navigating regulatory mazes, partnering with pharma & the many fires that consist of operating an early stage company. We’ve been in your shoes before, we pride ourselves in being the VC we wish we had on our own cap tables, founders we are here to help! 

SAB/MAB: Composed of top VC-backed PhD Life Sciences founders, our scientific & medical advisory board aids our investment team in both technical & clinical diligence - thus providing a multitude of expertise & fluency across a wide variety of Life Science sub-domains. Let’s talk science!

Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our operating partner - Mark Pulido (5x HC/LS CEO - previously of Novartis, McKesson, & Ability) & our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large payors.

Limited Partners: Anchored by leading strategic LPs making up some of the best venture capital firms in the world, veteran founders, & industry experts. Alix is here to fill the void for early stage Life Sciences specific capital in Silicon Valley.

news impact assignment basic	general
public peers	general	Nov 6, 2024 11:04 PM	7f25feb4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 11:04 PM	a72a75ad
crunchbase trigger	general	Nov 6, 2024 11:04 PM	6eb0fe97
crunchbase profile	general	Nov 7, 2024 6:29 PM	cd24a674
li profile	general	Nov 6, 2024 11:04 PM	32c50a88
translate crunchbase fundingrounds	general	Nov 7, 2024 7:12 PM	d6122e46
peers	general	Nov 6, 2024 11:04 PM	16af32dd
news basic	general	Nov 6, 2024 11:04 PM	d3af4907
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ALIX

VC:ALIX

Alix Ventures